Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

doxycycline hyclate matrix formulation

An extended release (ER) formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, in a biodegradable, polymer-lipid encapsulation matrix (PLEX), with antimicrobial activity. Following reconstitution and administration in the surgical wound/incision, doxycycline is released from the matrix over an extended period of time. Upon release, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis. This may prevent surgical site infections.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:doxycycline hyclate matrix extended-release formulation
doxycycline polymer-lipid encapsulation matrix formulation
US brand name:D-PLEX
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search